Jane Street Group LLC Makes New Investment in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)

Jane Street Group LLC bought a new position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 39,057 shares of the company’s stock, valued at approximately $77,000. Jane Street Group LLC owned 0.15% of MAIA Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).

MAIA Biotechnology Stock Performance

NYSEAMERICAN:MAIA opened at $1.80 on Monday. The firm has a 50-day simple moving average of $1.79 and a 200-day simple moving average of $2.07. MAIA Biotechnology, Inc. has a one year low of $1.40 and a one year high of $4.24. The firm has a market cap of $47.09 million, a P/E ratio of -1.30 and a beta of 0.20.

Insiders Place Their Bets

In other MAIA Biotechnology news, Director Stan Smith purchased 33,333 shares of MAIA Biotechnology stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average cost of $1.50 per share, with a total value of $49,999.50. Following the completion of the transaction, the director now owns 1,305,059 shares in the company, valued at approximately $1,957,588.50. This trade represents a 2.62% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 36.98% of the stock is currently owned by corporate insiders.

MAIA Biotechnology Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.